EGFR and non-small cell lung carcinoma: Several key phase III trials have demonstrated superior efficacy and progression-free survival (PFS) in patients treated with erlotinib or gefitinib versus standard chemotherapy regimens in patients with NSCLC exhibiting EGFR-sensitizing mutations, but no significant difference in overall survival (OS) was observed (33–37, 39, 42–45).